Answers are grounded in this paper and cite their sources.
Early detection of esophageal squamous cell carcinoma (ESCC) is hindered by a lack of noninvasive biomarkers for precancerous lesions. Here, we report a circulating cell-free DNA (cfDNA) methylation approach for early esophageal neoplasia detection. In prospective community screening, the assay achieved standardized sensitivity of 78% at 79% specificity for the clinically actionable endpoint of high-grade intraepithelial neoplasia (HGIN) or ESCC, with stage-specific sensitivities of 76% for HGIN and 86% for ESCC. Genome-wide methylation profiling reveals HGIN as an early epigenetic reprogramming stage. Integrative spatial and single-cell RNA sequencing reveals pronounced remodeling of the endothelial-proximal epithelial cell population, whose methylation signatures are detected in cfDNA. Guided by these findings, we develop an 11-gene cfDNA methylation panel that shows robust discrimination of early-stage ESCC across three retrospective case-control sets and an independent screening-derived case-control set. Together, these results demonstrate that our cfDNA methylation panel has promising utility for early ESCC detection.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: